$261.3 M

MIRN Mkt cap, 31-Aug-2018

$1.8 M

Mirna Therapeutics Revenue Q3, 2018
Mirna Therapeutics Net income (Q3, 2018)-10.7 M
Mirna Therapeutics EBIT (Q3, 2018)-11.5 M
Mirna Therapeutics Cash, 30-Sep-201817.3 M

Mirna Therapeutics Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017

Revenue

2.4m

R&D expense

18.9m13.9m30.3m

General and administrative expense

6.1m8.1m12.9m

Operating expense total

25.0m26.6m43.3m

EBIT

(40.8m)

EBIT margin, %

(1670%)

Interest expense

57.0k

Interest income

44.0k350.0k

Net Income

(25.0m)(26.3m)(40.4m)

Quarterly

USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

111.0k354.0k254.0k1.8m

R&D expense

4.5m3.7m3.4m9.0m8.4m10.9m9.9m

General and administrative expense

1.6m2.1m2.0m1.9m3.2m3.6m4.7m3.4m

Operating expense total

6.2m6.7m5.7m5.3m12.2m12.0m15.6m13.3m

EBIT

(12.1m)(11.6m)(15.4m)(11.5m)

EBIT margin, %

(10878%)(3287%)(6044%)(640%)

Interest expense

8.0k7.0k14.0k12.0k10.0k

Interest income

82.0k93.0k97.0k

Net Income

(6.2m)(6.6m)(5.6m)(5.4m)(11.9m)(11.2m)(14.6m)(10.7m)

Mirna Therapeutics Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017

Cash

89.7m16.4m58.4m

Inventories

793.0k882.0k

Current Assets

90.5m61.4m88.6m

PP&E

375.0k354.0k9.8m

Total Assets

90.9m64.2m99.7m

Accounts Payable

3.7m361.0k2.7m

Current Liabilities

5.9m2.8m9.0m

Non-Current Liabilities

5.6m

Total Liabilities

3.8m

Additional Paid-in Capital

161.5m163.1m156.7m

Retained Earnings

(76.5m)(102.8m)(71.7m)

Total Equity

85.0m60.4m

Financial Leverage

1.1 x1.1 x

Quarterly

USDQ3, 2015Q2, 2016Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

35.7m30.8m15.2m79.2m27.2m26.6m17.3m

Accounts Receivable

2.0m

Current Assets

36.1m73.5m48.1m98.2m127.9m145.3m136.0m

PP&E

266.0k1.2m13.0k13.7m14.6m14.9m

Total Assets

38.1m77.2m48.1m104.5m142.7m161.1m152.0m

Accounts Payable

2.2m1.5m47.0k956.0k1.3m1.1m3.4m

Current Liabilities

5.0m1.4m8.0m7.0m8.2m8.9m

Non-Current Liabilities

944.0k6.9m8.3m8.1m

Total Liabilities

3.7m1.4m

Additional Paid-in Capital

162.2m163.8m155.5m211.4m241.8m242.9m

Retained Earnings

(67.7m)(88.7m)(117.2m)(60.0m)(82.5m)(97.1m)(107.8m)

Total Equity

73.5m46.7m95.6m128.8m144.6m135.0m

Financial Leverage

1 x1 x1.1 x1.1 x1.1 x1.1 x

Mirna Therapeutics Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017

Net Income

(25.0m)(26.3m)(40.4m)

Depreciation and Amortization

54.0k159.0k2.3m

Inventories

793.0k107.0k

Accounts Payable

3.7m(3.3m)4.1m

Cash From Operating Activities

(21.1m)(24.8m)

Purchases of PP&E

(251.0k)(1.7m)(2.6m)

Cash From Investing Activities

(251.0k)(48.5m)

Cash From Financing Activities

67.0k16.0k

Interest Paid

35.0k

Quarterly

USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(6.2m)(6.6m)(5.6m)(5.4m)(28.7m)(11.2m)(25.8m)(36.5m)

Depreciation and Amortization

1.3m681.0k1.2m1.8m

Accounts Receivable

(2.0m)

Accounts Payable

2.2m1.2m1.5m1.2m371.0k47.0k2.9m(3.0m)(1.3m)(592.0k)

Cash From Operating Activities

(22.0m)(13.0m)(23.8m)(33.5m)

Purchases of PP&E

(2.5m)(1.9m)(2.9m)(4.3m)

Cash From Investing Activities

19.7m(71.9m)(90.4m)(90.1m)

Cash From Financing Activities

66.9m53.6m82.4m82.4m

Interest Paid

22.0k14.0k25.0k35.0k

Mirna Therapeutics Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information

Mirna Therapeutics Operating Metrics

FY, 2016

Patents Issued

10

Patents Pending

42
Report incorrect company information